Our Technology

Developing Designer ECM Therapy

XM Therapeutics aims to improve the health of patients with chronic disorders by developing a new class of therapeutic products that can modulate and repair the dysfunctional Extracellular Matrix (ECM). This matrix is found in most chronic diseases, where it contributes to inflammation, fibrosis, and poor oxygen supply. In the past, understanding the ECM remodeling process and how to intervene was challenging due to the complexity of the interactions between thousands of molecules and cells. However, new technologies like proteomic profiling and big data analytics have made it possible to characterize healthy and abnormal ECM in specific tissues and organs, opening up new possibilities for tissue repair in conditions such as heart failure, pulmonary fibrosis, liver disease and kidney failure.

The company's focus is initially on the heart and lungs, where they are designing ECM particles specific to those organs and their disease states. XM Therapeutics' initial ECM particle formulations are in the pre-clinical testing stage and will not be available for clinical use in the near future. Developing effective therapies to intervene in dysfunctional ECM remodeling is critical, and XM Therapeutics is working to create practical, reproducible, and scalable therapies to make a significant impact in the field.

Previous and other ECM technologies and research have largely been based on animal biology, which can be problematic when developing therapies for humans. In contrast, XM Therapeutics' technology is based on human biology, which makes it more compatible, safer, and more effective.

1950s 

Researchers first began to understand the complex matrix of proteins and other molecules that surround cells in tissues throughout the body. Early work focused on identifying the major structural components of ECM, such as collagen and elastin, and characterizing their physical properties.

2000 

Advancements in technology, such as mass spectrometry and proteomic profiling, allowed researchers to gain a deeper understanding of the composition and function of ECM in various tissues and organs, including cell adhesion, migration and differentiation.

Now 

Increasing interest in using ECM as a therapeutic target for a wide range of chronic diseases, including heart failure, pulmonary fibrosis, and liver disease. Researchers are now exploring new technologies to develop therapies that can modulate and repair dysfunctional ECM, such as XM Therapeutics' approach of developing designer ECM particles to repair damaged organs.